Evommune Initiates Phase 2b Trial of its Oral MRGPRX2 Antagonist, EVO756, in Adults with Moderate to Severe Atopic Dermatitis

MRGPRX2 antogonism is the only known mechanism of action designed to modulate mast cells and sensory neurons, both key drivers in the neuroimmune interaction that drives lesions and intense itch in atopic dermatitis (AD) EVO756 is specifically designed to address the need for a safe and...